Merck has announced the acquisition of Verona Pharma for 10 billion dollars, strengthening its portfolio of respiratory treatments.
Raluca Ioana Draghici
.webp)
Economy
www.shutterstock.com
Always see our news on Google
Pharmaceutical giant Merck has decided to acquire the British company Verona Pharma for about 10 billion dollars, paying 107 dollars per share, a 23% premium. The strategic move comes amid Merck's desire to diversify its revenue streams, given that the patent for its Keytruda oncology treatment will expire in 2028. This is a continuation of Merck's efforts to expand its portfolio, given previous acquisitions including Prometheus Biosciences.
Sources
Latest News
22:57
Prosecutor seeks sentences of up to 12 years for three doctors accused in the death of Diego Maradona
22:53
Donald Trump calls those who use the term “artificial intelligence” instead of “Super Intelligence” “enemies”
22:42
A bison weighing over 800 kilograms was found dead and decapitated in Măgura Ilvei. The police are investigating the case
22:30
George Simion, comment on Luca Niculescu's post about negotiations with the parties: “So, will you be the prime minister in the PSD government?”
22:28
Trump promises that the US will not resume attacks before the midterm elections
See more news
NEWS ON THE SAME TOPICS
International
AstraZeneca, negotiations with Bristol Myers Squibb for a possible merger that could create a 400 billion dollar group
International
An experimental cancer vaccine, developed by Moderna and Merck, has shown promising results in patients with melanoma.
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
